A form of ischemia-reperfusion injury occurring in the early period following transplantation. Significant pathophysiological changes in MITOCHONDRIA are the main cause of the dysfunction. It is most often seen in the transplanted lung, liver, or kidney and can lead to GRAFT REJECTION.
The transference of either one or both of the lungs from one human or animal to another.
A fibrillar collagen found widely distributed as a minor component in tissues that contain COLLAGEN TYPE I and COLLAGEN TYPE III. It is a heterotrimeric molecule composed of alpha1(V), alpha2(V) and alpha3(V) subunits. Several forms of collagen type V exist depending upon the composition of the subunits that form the trimer.
Individuals supplying living tissue, organs, cells, blood or blood components for transfer or transplantation to histocompatible recipients.
Inflammation of the BRONCHIOLES leading to an obstructive lung disease. Bronchioles are characterized by fibrous granulation tissue with bronchial exudates in the lumens. Clinical features include a nonproductive cough and DYSPNEA.
The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.
Elements of limited time intervals, contributing to particular results or situations.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
The transference of a kidney from one human or animal to another.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
The transference of a part of or an entire liver from one human or animal to another.
General dysfunction of an organ occurring immediately following its transplantation. The term most frequently refers to renal dysfunction following KIDNEY TRANSPLANTATION.

Association between primary graft dysfunction among lung, kidney and heart recipients from the same multiorgan donor. (1/98)

 (+info)

Impact of human donor lung gene expression profiles on survival after lung transplantation: a case-control study. (2/98)

 (+info)

Late primary graft dysfunction after lung transplantation and bronchiolitis obliterans syndrome. (3/98)

 (+info)

Plasma cytokines and chemokines in primary graft dysfunction post-lung transplantation. (4/98)

 (+info)

Participation of autophagy in the initiation of graft dysfunction after rat liver transplantation. (5/98)

Better ways to prevent the cold ischemia-warm reperfusion (CI/WR) injury associated with liver transplantation are needed, and many investigations have focused on the molecular mechanisms of this injury. However, the mechanisms reported to date are controversial and no improvement in therapy has resulted. Here, using prolonged CI and orthotopic transplantation of rat liver grafts, we found that the CI/WR injury was closely associated with autophagy. By 15 minutes after the start of WR, small masses of hepatocytes that possessed abundant autophagosomes and autolysosomes frequently dissociated from the hepatic cords and obstructed the sinusoid, causing massive necrosis of hepatocytes within 2 hours. The cell masses included TUNEL-positive nuclei without caspase-3 and -7 activation. Autophagy suppression with the phosphatidylinositol 3-kinase (PI3K) inhibitors, wortmannin or LY294002, reduced both liver damage and the mortality rate of recipient rats. To elucidate the downstream mechanisms of this autophagic pathway, liver grafts were treated with aspartic and cysteine proteinase inhibitors, pepstatin and leupeptin. This treatment also significantly improved the survival rate of recipient rats. These data suggest that autophagy-associated hepatocyte death triggers liver graft dysfunction. The protective effects of suppressing autophagy may suggest new ways to prevent CI/WR injury of the liver.  (+info)

Does anaesthetic management affect early outcomes after lung transplant? An exploratory analysis. (6/98)

 (+info)

Concurrent Kaposi's sarcoma, tuberculosis, and allograft dysfunction in a renal transplant patient. (7/98)

The major long-term complications of renal transplantation (RT) include cardio-vascular disease, opportunistic infections, malignancies, and chronic allograft nephropathy. Long-term complications are generally considered as those occurring more than 1 year post trans-plantation; however, some of the complications can occur earlier. We present a 58-year-old man who presented with multiple complications of RT concurrently and relatively early post trans-plantation including Kaposi's sarcoma, tuberculosis and allograft dysfunction.  (+info)

Soluble p-selectin and the risk of primary graft dysfunction after lung transplantation. (8/98)

 (+info)

Primary graft dysfunction (PGD) is a severe complication that can occur after an organ transplant, such as a lung or heart transplant. It refers to the early functional impairment of the grafted organ that is not due to surgical complications, rejection, or recurrence of the original disease.

In the case of lung transplants, PGD is defined as the evidence of poor oxygenation and stiffness in the lungs within the first 72 hours after the transplant. It is typically caused by inflammation, injury to the blood vessels, or other damage to the lung tissue during the transplant procedure or due to pre-existing conditions in the donor organ.

PGD can lead to serious complications, including respiratory failure, and is associated with increased morbidity and mortality after transplantation. Treatment may include supportive care, such as mechanical ventilation and medications to support lung function, as well as strategies to reduce inflammation and prevent further damage to the grafted organ.

Lung transplantation is a surgical procedure where one or both diseased lungs are removed and replaced with healthy lungs from a deceased donor. It is typically considered as a treatment option for patients with end-stage lung diseases, such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, idiopathic pulmonary fibrosis, and alpha-1 antitrypsin deficiency, who have exhausted all other medical treatments and continue to suffer from severe respiratory failure.

The procedure involves several steps, including evaluating the patient's eligibility for transplantation, matching the donor's lung size and blood type with the recipient, and performing the surgery under general anesthesia. After the surgery, patients require close monitoring and lifelong immunosuppressive therapy to prevent rejection of the new lungs.

Lung transplantation can significantly improve the quality of life and survival rates for some patients with end-stage lung disease, but it is not without risks, including infection, bleeding, and rejection. Therefore, careful consideration and thorough evaluation are necessary before pursuing this treatment option.

Collagen Type V is a specific type of collagen, which is a protein that provides structure and strength to connective tissues in the body. Collagen Type V is found in various tissues, including the cornea, blood vessels, and hair. It plays a crucial role in the formation of collagen fibers and helps regulate the diameter of collagen fibrils. Mutations in the genes that encode for Collagen Type V can lead to various connective tissue disorders, such as Ehlers-Danlos syndrome and osteogenesis imperfecta.

A tissue donor is an individual who has agreed to allow organs and tissues to be removed from their body after death for the purpose of transplantation to restore the health or save the life of another person. The tissues that can be donated include corneas, heart valves, skin, bone, tendons, ligaments, veins, and cartilage. These tissues can enhance the quality of life for many recipients and are often used in reconstructive surgeries. It is important to note that tissue donation does not interfere with an open casket funeral or other cultural or religious practices related to death and grieving.

Bronchiolitis obliterans is a medical condition characterized by the inflammation and scarring (fibrosis) of the bronchioles, which are the smallest airways in the lungs. This results in the narrowing or complete obstruction of the airways, leading to difficulty breathing and reduced lung function.

The condition is often caused by a respiratory infection, such as adenovirus or mycoplasma pneumonia, but it can also be associated with exposure to certain chemicals, drugs, or radiation therapy. In some cases, the cause may be unknown.

Symptoms of bronchiolitis obliterans include cough, shortness of breath, wheezing, and crackles heard on lung examination. Diagnosis typically involves a combination of medical history, physical exam, imaging studies (such as chest X-ray or CT scan), and pulmonary function tests. In some cases, a biopsy may be necessary to confirm the diagnosis.

Treatment for bronchiolitis obliterans is focused on managing symptoms and preventing further lung damage. This may include bronchodilators to help open up the airways, corticosteroids to reduce inflammation, and oxygen therapy to help with breathing. In severe cases, a lung transplant may be necessary.

Graft survival, in medical terms, refers to the success of a transplanted tissue or organ in continuing to function and integrate with the recipient's body over time. It is the opposite of graft rejection, which occurs when the recipient's immune system recognizes the transplanted tissue as foreign and attacks it, leading to its failure.

Graft survival depends on various factors, including the compatibility between the donor and recipient, the type and location of the graft, the use of immunosuppressive drugs to prevent rejection, and the overall health of the recipient. A successful graft survival implies that the transplanted tissue or organ has been accepted by the recipient's body and is functioning properly, providing the necessary physiological support for the recipient's survival and improved quality of life.

Graft rejection is an immune response that occurs when transplanted tissue or organ (the graft) is recognized as foreign by the recipient's immune system, leading to the activation of immune cells to attack and destroy the graft. This results in the failure of the transplant and the need for additional medical intervention or another transplant. There are three types of graft rejection: hyperacute, acute, and chronic. Hyperacute rejection occurs immediately or soon after transplantation due to pre-existing antibodies against the graft. Acute rejection typically occurs within weeks to months post-transplant and is characterized by the infiltration of T-cells into the graft. Chronic rejection, which can occur months to years after transplantation, is a slow and progressive process characterized by fibrosis and tissue damage due to ongoing immune responses against the graft.

In the field of medicine, "time factors" refer to the duration of symptoms or time elapsed since the onset of a medical condition, which can have significant implications for diagnosis and treatment. Understanding time factors is crucial in determining the progression of a disease, evaluating the effectiveness of treatments, and making critical decisions regarding patient care.

For example, in stroke management, "time is brain," meaning that rapid intervention within a specific time frame (usually within 4.5 hours) is essential to administering tissue plasminogen activator (tPA), a clot-busting drug that can minimize brain damage and improve patient outcomes. Similarly, in trauma care, the "golden hour" concept emphasizes the importance of providing definitive care within the first 60 minutes after injury to increase survival rates and reduce morbidity.

Time factors also play a role in monitoring the progression of chronic conditions like diabetes or heart disease, where regular follow-ups and assessments help determine appropriate treatment adjustments and prevent complications. In infectious diseases, time factors are crucial for initiating antibiotic therapy and identifying potential outbreaks to control their spread.

Overall, "time factors" encompass the significance of recognizing and acting promptly in various medical scenarios to optimize patient outcomes and provide effective care.

A biological marker, often referred to as a biomarker, is a measurable indicator that reflects the presence or severity of a disease state, or a response to a therapeutic intervention. Biomarkers can be found in various materials such as blood, tissues, or bodily fluids, and they can take many forms, including molecular, histologic, radiographic, or physiological measurements.

In the context of medical research and clinical practice, biomarkers are used for a variety of purposes, such as:

1. Diagnosis: Biomarkers can help diagnose a disease by indicating the presence or absence of a particular condition. For example, prostate-specific antigen (PSA) is a biomarker used to detect prostate cancer.
2. Monitoring: Biomarkers can be used to monitor the progression or regression of a disease over time. For instance, hemoglobin A1c (HbA1c) levels are monitored in diabetes patients to assess long-term blood glucose control.
3. Predicting: Biomarkers can help predict the likelihood of developing a particular disease or the risk of a negative outcome. For example, the presence of certain genetic mutations can indicate an increased risk for breast cancer.
4. Response to treatment: Biomarkers can be used to evaluate the effectiveness of a specific treatment by measuring changes in the biomarker levels before and after the intervention. This is particularly useful in personalized medicine, where treatments are tailored to individual patients based on their unique biomarker profiles.

It's important to note that for a biomarker to be considered clinically valid and useful, it must undergo rigorous validation through well-designed studies, including demonstrating sensitivity, specificity, reproducibility, and clinical relevance.

Kidney transplantation is a surgical procedure where a healthy kidney from a deceased or living donor is implanted into a patient with end-stage renal disease (ESRD) or permanent kidney failure. The new kidney takes over the functions of filtering waste and excess fluids from the blood, producing urine, and maintaining the body's electrolyte balance.

The transplanted kidney is typically placed in the lower abdomen, with its blood vessels connected to the recipient's iliac artery and vein. The ureter of the new kidney is then attached to the recipient's bladder to ensure proper urine flow. Following the surgery, the patient will require lifelong immunosuppressive therapy to prevent rejection of the transplanted organ by their immune system.

Prospective studies, also known as longitudinal studies, are a type of cohort study in which data is collected forward in time, following a group of individuals who share a common characteristic or exposure over a period of time. The researchers clearly define the study population and exposure of interest at the beginning of the study and follow up with the participants to determine the outcomes that develop over time. This type of study design allows for the investigation of causal relationships between exposures and outcomes, as well as the identification of risk factors and the estimation of disease incidence rates. Prospective studies are particularly useful in epidemiology and medical research when studying diseases with long latency periods or rare outcomes.

Liver transplantation is a surgical procedure in which a diseased or failing liver is replaced with a healthy one from a deceased donor or, less commonly, a portion of a liver from a living donor. The goal of the procedure is to restore normal liver function and improve the patient's overall health and quality of life.

Liver transplantation may be recommended for individuals with end-stage liver disease, acute liver failure, certain genetic liver disorders, or liver cancers that cannot be treated effectively with other therapies. The procedure involves complex surgery to remove the diseased liver and implant the new one, followed by a period of recovery and close medical monitoring to ensure proper function and minimize the risk of complications.

The success of liver transplantation has improved significantly in recent years due to advances in surgical techniques, immunosuppressive medications, and post-transplant care. However, it remains a major operation with significant risks and challenges, including the need for lifelong immunosuppression to prevent rejection of the new liver, as well as potential complications such as infection, bleeding, and organ failure.

Delayed graft function (DGF) is a term used in the medical field, particularly in transplant medicine. It refers to a situation where a transplanted organ, most commonly a kidney, fails to function normally immediately after the transplantation procedure. This failure to function occurs within the first week after the transplant and is usually associated with poor urine output and elevated levels of creatinine in the blood.

DGF can be caused by several factors, including pre-existing conditions in the recipient, such as diabetes or hypertension, poor quality of the donor organ, or complications during the surgery. It may also result from the immune system's reaction to the transplanted organ, known as rejection.

In many cases, DGF can be managed with medical interventions, such as administering medications to help reduce inflammation and improve blood flow to the organ. However, in some instances, it may lead to more severe complications, including acute or chronic rejection of the transplanted organ, which could require additional treatments or even another transplant.

It's important to note that not all cases of DGF lead to long-term complications, and many patients with DGF can still go on to have successful transplants with proper management and care.

Learn about Primary Graft Dysfunction at online-medical-dictionary.org ... It is most often seen in the transplanted lung, liver, or kidney and can lead to GRAFT REJECTION. ... Significant pathophysiological changes in MITOCHONDRIA are the main cause of the dysfunction. ... Dysfunction, Primary Graft. Graft Dysfunction, Primary. A form of ischemia-reperfusion injury occurring in the early period ...
... referred to as severe graft dysfunction.. RESULTS: Of the total cohort (n... (More). INTRODUCTION: Primary graft dysfunction ( ... INTRODUCTION: Primary graft dysfunction (PGD) is a leading cause of 30-day mortality following heart transplantation, and early ... Myocardial injury biomarkers at point of care for early identification of primary graft dysfunction after heart transplantation ... article{8f4df24a-c2ad-420c-9369-1b2a8bae7b50, abstract = {{,p,INTRODUCTION: Primary graft dysfunction (PGD) is a leading cause ...
ISHLT Working Group on Primary Lung Graft Dysfunction. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part ... Primary graft dysfunction. Acute lung injury of newly transplanted lungs has been called numerous names; however, the term ... Late primary graft dysfunction after lung transplantation and bronchiolitis obliterans syndrome. Am J Transplant. Nov 2008. 8: ... 70] This new model may provide investigators a new path to study perplexing problems such as BO and primary graft dysfunction ( ...
... Galeone A. ;Varnous S;Salem J;Lebreton G;Coutance G;Hulot J;Leprince P. 2018-01- ... Recipients who needed a postoperative ecmo for primary graft dysfunction had significantly higher serum levels of sST2 in their ... Recipients who needed a postoperative ecmo for primary graft dysfunction had significantly higher serum levels of sST2 in their ... Conclusion: Higher sST2 serum levels in donors are associated with primary graft dysfunction in recipients; higher sST2 serum ...
Reduction of primary graft dysfunction using cytokine adsorption during organ preservation and after lung transplantation * ... Reduction of primary graft dysfunction using cytokine adsorption during organ preservation and after lung transplantation * ... Soluble P-selectin and the risk of primary graft dysfunction after lung transplantation. Chest 136, 237-244 (2009). ... Interleukin-8 release during early reperfusion predicts graft function in human lung transplantation. Am. J. Respir. Crit. Care ...
abstract = "Primary graft dysfunction (PGD) is the leading cause of morbidity and mortality in the first 30 days after lung ... N2 - Primary graft dysfunction (PGD) is the leading cause of morbidity and mortality in the first 30 days after lung ... AB - Primary graft dysfunction (PGD) is the leading cause of morbidity and mortality in the first 30 days after lung ... Primary graft dysfunction (PGD) is the leading cause of morbidity and mortality in the first 30 days after lung transplantation ...
Donor Hypernatremia is Not Related with the Duration of Postoperative Mechanical Ventilation, Primary Graft Dysfunction, or ... Donor Hypernatremia is Not Related with the Duration of Postoperative Mechanical Ventilation, Primary Graft Dysfunction, or ... Donor Hypernatremia is Not Related with the Duration of Postoperative Mechanical Ventilation, Primary Graft Dysfunction, or ... Donor Hypernatremia is Not Related with the Duration of Postoperative Mechanical Ventilation, Primary Graft Dysfunction, or ...
10 January 2013). "Clinical risk factors for primary graft dysfunction after lung transplantation". American Journal of ...
Report primary graft dysfunction in heart transplant recipients. Changes implemented with this policy modify the Heart and ...
Overcoming primary graft dysfunction after lung transplantation: are we finding our way there? Bertani A. Bertani A. ... A project to assess the quality of the published guidelines for managing primary spontaneous pneumothorax from the Italian ...
1. Soluble P-Selectin and the Risk of Primary Graft Dysfunction After Lung Transplantation Kawut, Steven M.; Okun, Jeffrey; ...
Poor function of the transplanted lungs (primary graft dysfunction). *Infection. *Acute rejection ...
... which leads to primary graft dysfunction and affects patients survival rate. Bone marrow mesenchymal stem cells (BMSCs) have ... which leads to primary graft dysfunction and affects patients survival rate. Bone marrow mesenchymal stem cells (BMSCs) have ... of recipients have suffered from primary graft dysfunction (PGD) after heart transplantation(3). ... graft dysfunction after heart transplantation and that these cardioprotective effects could be enhanced by hypoxic ...
Chronic graft dysfunction, intensifying immunosuppression, and SARS-CoV-2 infection in this patient could have favored ... His primary research interests are emerging pathogens and antimicrobial drug resistance.. Top ... In 2021, she experienced progressive graft dysfunction with no obvious trigger and was treated with alemtuzumab in June 2021. ... It is possible that the chronic graft dysfunction, the recent intensification of immunosuppression, and the SARS-CoV-2 ...
The primary endpoint was early allograft dysfunction (EAD). We analyzed multiple secondary endpoints including postoperative ... graft rejection, graft survival, Hepatic Artery, Hospital Mortality, Humans, incidence, Kidney Function Tests, length of stay, ... Among the postoperative graft function parameters, postoperative alanine aminotransferase level was significantly lower in the ... Abstract : The role of prostaglandin E1 (PGE1) infusion in improving early graft function has not been well defined, especially ...
Develop Measures for Primary Graft Dysfunction in Hearts Heart Transplantation Proposal. Update Transplant Program Key ...
Short Airway Telomeres are Associated with Primary Graft Dysfunction and Chronic Lung Allograft Dysfunction. J Heart Lung ... Lung Allograft Epithelium DNA Methylation Age Is Associated With Graft Chronologic Age and Primary Graft Dysfunction. Front ... Pulmonary Hypertension and Primary Graft Dysfunction in Lung Transplant Recipients: We Still Have a Long Way to Go. Ann Am ... The Clinical and Molecular Impacts of Lung Primary Graft Dysfunction. NHLBI U01-HL163294May 14, 2022 - May 14, 2027. Role: Co-I ...
Primary graft dysfunction attenuates improvements in health-related quality of life after lung transplantation, but not ... Preventing occupational illness and injury: nurse practitioners as primary care providers.. American journal of public health ... Depressive symptoms in lung transplant recipients: trajectory and association with mortality and allograft dysfunction.. Thorax ...
Pre-Procurement In Situ Donor Lung Tissue Gene Expression Classifies Primary Graft Dysfunction Risk Am J Respir Crit Care Med ... Extended post-ex vivo lung perfusion cold preservation predicts primary graft dysfunction and mortality: Results from a ... Primary Location. Penn Heart and Vascular Center Perelman Center for Advanced Medicine. East Pavilion, 2nd Floor. 3400 Civic ...
Spectral Doppler ultrasonogram of the portal vein was obtained at the onset of graft dysfunction. Compared with the baseline ... Recurrent primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis after transplantation. Semin ... Spectral Doppler ultrasonogram of the portal vein was obtained at the onset of graft dysfunction. Compared with the baseline ... Other than excluding other causes of graft dysfunction, the modalities are not helpful in diagnosing recurrent hepatitis B ...
Primary graft dysfunction attenuates improvements in health-related quality of life after lung transplantation, but not ... NKG2D receptor activation drives primary graft dysfunction severity and poor lung transplantation outcomes. JCI Insight. 2022 ... Bronchoalveolar Lavage MICB is Associated with Severe Primary Graft Dysfunction, Prolonged Mechanical Ventilation, and Low Post ... BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree ...
NKG2D receptor activation drives primary graft dysfunction severity and poor lung transplantation outcomes. JCI Insight. 2022 ... Bronchoalveolar Lavage MICB is Associated with Severe Primary Graft Dysfunction, Prolonged Mechanical Ventilation, and Low Post ...
Re-transplantation remains the only therapeutic option in some cases of severe primary graft dysfunction, severe untreatable ... Graft survival of re-transplantation (median survival 76 months; 95% CI 22.2-115.7) was comparable to that of primary ... 30-day transplant survival was 89.1%; causes of early death or graft failure were multi-organ failure, primary transplant ... graft versus host disease and primary pulmonary hypertension).. 5 yrs post-transplant, kidney function was impaired in 66.7% of ...
6. Cytokine Biomarkers as Indicators of Primary Graft Dysfunction, Acute Rejection, and Chronic Lung Allograft Dysfunction in ...
Biomarkers of lung injury in primary graft dysfunction following lung transplantation. Biomark Med. 2007;1(2):285-291. ... Bae KM, Wang H, Jiang G, Chen MG, Lu L, Xiao L. Protein kinase C epsilon is overexpressed in primary human non-small cell lung ... Culture and laboratory study of airway epithelium from patients with primary ciliary dyskinesia. Presented at the International ... Reversal of chronic rhinosinusitis-associated sinonasal ciliary dysfunction. Am J Rhinol. 2007;21(3):346-353. ...
The analysis showed a statistically significant 72% reduction p=0.005) in Severe Primary Graft Dysfunction (PGD) rates.1,2 The ... 71.9% reduction in Severe PGD (primary graft dysfunction) (p=0.005)1,2 ...
Primary graft dysfunction after living donor liver transplantation is characterized by delayed functional hyperbilirubinemia. ... Organ survival after primary dysfunction of liver grafts in clinical orthotopic liver transplantation. ... Primary graft dysfunction of the liver: definitions, diagnostic criteria and risk factors. ... Impact of early graft dysfunction on two-year survival. One Kaplan-Meier curve is presented for each diagnostic method applied ...
Oxidative phosphorylation and mitochondrial dysfunction were the top molecular pathways associated with overexpressed genes in ... samples served as positive controls to validate CNIT marker specificity and were characterized by other common causes of graft ... has been associated with the development of chronic renal allograft dysfunction and decreased graft survival. This study ... Although it was not our primary objective to characterize the molecular profiles of AR and IFTA samples, we did observe ...
The incidence of primary graft dysfunction-a post-operative condition that leads to early morbidity and mortality in lung ... Once A1AT reaches lung cells, its primary role is to block signal transduction pathways triggering the production of ...

No FAQ available that match "primary graft dysfunction"

No images available that match "primary graft dysfunction"